Benchmark Reiterates Buy Rating on Emergent BioSolutions (EBS)

June 2, 2026 8:40 AM EDT Send to a Friend
Benchmark analyst Robert Wasserman reiterated a Buy rating and $12.00 price target on Emergent BioSolutions (NYSE: EBS).The analyst commented, "Emergent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login